logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
O

Oliver Gassmann

University of St Gallen

69H指数
1.0K论文数
2.3W被引数
收录论文 74
发表时间
logo
Reassessing R&D outcomes of leading pharmaceutical companies重新评估领先制药公司的研发成果
errDrug Discovery Today
IF7.5
err2026-08-11
err0
errOAAI
errAlexander Schuhmacher; Michael Witting; Dominik Hartl; Markus Hinder; Oliver Gassmann
err分享
err收藏
Rethinking manufacturer-dealer relationships for customer solutions: From a single to a portfolio of relationship modes重新思考制造商-经销商关系以实现客户解决方案：从单一关系到关系模式组合
errInternational Journal of Production Economics
IF10
err2026-08-01
err0
PREAI
errKnapp, Johanna Luisa; Gebauer, Heiko; Gassmann, Oliver; Wortmann, Felix
err分享
err收藏
New perspectives for better R&D performance: lessons learned from leading pharma companies提升研发绩效的新视角：来自领先制药公司的经验教训
errDrug Discovery Today
IF7.5
err2026-04-17
err0
errOAAI
errAlexander Schuhmacher; Oliver Gassmann; Sara Knapp; Dominik Hartl; Markus Hinder
err分享
err收藏
The R&D productivity challenge: transforming the pharmaceutical ecosystem研发生产力挑战：变革制药生态系统
errDrug Discovery Today
IF7.5
err2025-10-09
err0
errOAAI
errAlexander Schuhmacher; Oliver Gassmann; Sebastian Kwisda; Malte Kremer; Markus Hinder; Dominik Hartl
err分享
err收藏
Does pharma R&D need a strategic reset? Adapting to a changing US landscape制药研发是否需要战略重置？适应变化的美国格局
errDrug Discovery Today
IF7.5
err2025-07-28
err0
errOAAI
errSebastian Kwisda; Malte Kremer; Niels Sievertsen; Oliver Gassmann; Dominik Hartl; Alexander Schuhmacher
err分享
err收藏
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022) (vol 30, 104291, 2025)对领先制药公司研发成功率进行基准测试：一项关于FDA批准（2006-2022年）的实证分析（卷30，104291，2025）
errDRUG DISCOVERY TODAY
IF7.5
err2025-05-01
err0
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Brief, Elazar; Gassmann, Oliver; Hartl, Dominik
err分享
err收藏
A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies
errDRUG DISCOVERY TODAY
IF7.5
err2025-03-01
err0
errOAAI
errSchuhmacher, Alexander; Grinchenko, Kyrylo; Gassmann, Oliver; Hartl, Dominik; Hinder, Markus
err分享
err收藏
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)
errDRUG DISCOVERY TODAY
IF7.5
err2025-02-01
err0
errOAAI
errSchuhmacher, Alexander; Hinder, Markus; Brief, Elazar; Gassmann, Oliver; Hartl, Dominik
err分享
err收藏
Digital-sustainable business models: Definition, systematic literature review, integrative framework and research agenda from a strategic management perspective
errINTERNATIONAL JOURNAL OF MANAGEMENT REVIEWS
IF10.8
err2024-09-03
err3
errOAAI
errPalmie, Maximilian; Aebersold, Andreas; Oghazi, Pejvak; Pashkevich, Natallia; Gassmann, Oliver
err分享
err收藏
Comparative analysis of FDA approvals by top 20 pharma companies (2014-2023)前20家制药公司FDA批准的比较分析 (2014-2023)
errDRUG DISCOVERY TODAY
IF7.5
err2024-09-01
err2
errOAAI
errSchuhmacher, Alexander; Gassmann, Oliver; Hinder, Markus; Hartl, Dominik
err分享
err收藏
Implementing and scaling artificial intelligence: A review, framework, and research agenda实施和扩展人工智能: 回顾、框架和研究议程
errTECHNOLOGICAL FORECASTING AND SOCIAL CHANGE
IF13.3
err2023-12-01
err15
errOAAI
errHaefner, Naomi; Parida, Vinit; Gassmann, Oliver; Wincent, Joakim
err分享
err收藏
Is the blockbuster imperative broken
errDRUG DISCOVERY TODAY
IF7.5
err2023-11-01
err1
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Boger, Nikolaj; Gassmann, Oliver; Hartl, Dominik
err分享
err收藏
Analysis of pharma R&D productivity - a new perspective needed制药研发生产率分析 -- 需要一个新的视角
errDRUG DISCOVERY TODAY
IF7.5
err2023-10-01
err26
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Stein, Alexander von Stegmann und; Hartl, Dominik; Gassmann, Oliver
err分享
err收藏
Investigating the origins of recent pharmaceutical innovation
errNATURE REVIEWS DRUG DISCOVERY
IF101.8
err2023-07-05
err9
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Dodel, Alexander; Gassmann, Oliver; Hartl, Dominik
err分享
err收藏
Journey to the Big Bang: How firms define new value propositions in emerging ecosystems大爆炸之旅: 企业如何在新兴生态系统中定义新的价值主张
errJOURNAL OF ENGINEERING AND TECHNOLOGY MANAGEMENT
IF3.9
err2023-07-01
err6
PREAI
errLingens, Bernhard; Seeholzer, Veronika; Gassmann, Oliver
err分享
err收藏
Data-driven business and data privacy: Challenges and measures for product- based companies
errBUSINESS HORIZONS
IF7
err2023-07-01
err10
errOAAI
errSchafer, Fabian; Gebauer, Heiko; Groeger, Christoph; Gassmann, Oliver; Wortmann, Felix
err分享
err收藏
The dominant logic of Big Tech in healthcare and pharma医疗保健和制药领域大技术的主导逻辑
errDRUG DISCOVERY TODAY
IF7.5
err2023-02-01
err7
PREAI
errSchuhmacher, Alexander; Haefner, Naomi; Honsberg, Katharina; Goldhahn, Jorg; Gassmann, Oliver
err分享
err收藏
The significance of blockbusters in the pharmaceutical industry
errNATURE REVIEWS DRUG DISCOVERY
IF101.8
err2022-12-12
err9
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Boger, Nikolaj; Hartl, Dominik; Gassmann, Oliver
err分享
err收藏
The architecture of innovation: how firms configure different types of complementarities in emerging ecosystems创新架构: 企业如何在新兴生态系统中配置不同类型的互补性
errINDUSTRY AND INNOVATION
IF4.2
err2022-09-12
err7
PREAI
errLingens, Bernhard; Seeholzer, Veronika; Gassmann, Oliver
err分享
err收藏
Open innovation: A paradigm shift in pharma R&D?
errDRUG DISCOVERY TODAY
IF7.5
err2022-09-01
err24
PREAI
errSchuhmacher, Alexander; Gassmann, Oliver; Bieniok, Doria; Hinder, Markus; Hartl, Dominik
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
A
Andreas Herrmann
H 指数: 101 · 论文数: 1.3K
D
Dominik Hartl
H 指数: 67 · 论文数: 263
H
Henry Chesbrough
H 指数: 63 · 论文数: 206
J
Joakim Wincent
H 指数: 54 · 论文数: 253
H
Heiko Gebauer
H 指数: 50 · 论文数: 254
查看更多